A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of KUR-101 in Healthy Adults

This project tests the safety, tolerability, pharmacokinetics (PK, the amount of study drug in your blood) and pharmacodynamics (PD, how the study drug affects your body) of single doses of KUR-101 in 58 healthy participants.

This is a Phase I trial from atai Life Sciences. KUR-101 is an oral formulation of mitragynine, an alkaloid derived from the kratom plant. atai hopes that KUR-101 will effectively treat opioid use disorder (OUD) patients.

Topic Opioid Use Disorder
Compound Kratom
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

atai Life Sciences
atai Life Sciences is one of the biggest companies in the psychedelics field. The company aims to be a platform and has nine subsidiary companies working on everything from psilocybin for depression to DMT administration.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.